Clinical Trials Logo

Clinical Trial Summary

Although a great amount of research has been conducted to resolve cocaine dependence, an effective treatment has yet to be discovered. Topiramate is a drug that was found to be useful in treating alcohol dependence. The purpose of this study is to determine the effectiveness of topiramate in treating cocaine dependent individuals.


Clinical Trial Description

Despite considerable scientific effort in the last two decades to develop treatment for cocaine dependent individuals, no medication has proven to be effective for treating cocaine dependence. Cocaine's rewarding effects are primarily a result of altering nerve pathways involving dopamine, a naturally-occurring chemical in the brain. Past research has focused on developing medications that either block dopamine or inhibit its release. However, these medications have not proven effective in treating cocaine dependence. This study will evaluate a new strategy of treating cocaine dependence by altering dopamine's functional expression. Dopamine-associated expression may be mediated through inhibition of gamma-aminobutyric acid (GABA), another brain chemical. Topiramate is a GABA inhibitor that has proven effective in treating alcohol dependent individuals. The purpose of this study is to determine the efficacy of topiramate in treating cocaine dependent individuals.

Participants will be randomly assigned to receive either 300 mg per day of topiramate or placebo. In addition, participants will receive weekly cognitive behavioral therapy for 12 weeks. Follow-up visits will occur at 2 weeks and 1, 2, and 3 months following completion of treatment, and will include evaluations of cocaine use and psychosocial functioning. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00249691
Study type Interventional
Source University of Virginia
Contact
Status Active, not recruiting
Phase Phase 3
Start date October 2005
Completion date October 2012

See also
  Status Clinical Trial Phase
Completed NCT01526538 - Improving Learning-based Treatment of Cocaine Dependence With Medication Phase 2
Completed NCT00877435 - Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial N/A
Completed NCT00430690 - Acoustic Startle Reduction In Cocaine Dependence
Completed NCT00217997 - Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals N/A
Active, not recruiting NCT00094315 - Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1 Phase 1
Terminated NCT00142883 - The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3 N/A
Completed NCT00218348 - Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo Phase 2
Completed NCT00142844 - Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 Phase 2
Completed NCT00158132 - Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2 Phase 2
Completed NCT00015054 - Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3 Phase 2
Completed NCT00000294 - Effects of Carvedilol on Cocaine Use in Humans - 11 Phase 2
Completed NCT00000308 - Dextroamphetamine-Cocaine Behavioral Intervention - 5 Phase 2
Completed NCT00000188 - Selegiline in Treatment of Cocaine Dependence - 2 Phase 2
Completed NCT00000277 - Mazindol for Cocaine Abuse - 2 Phase 2
Terminated NCT00000276 - Dopamine Reuptake Inhibitors of Cocaine Abuse - 1 Phase 1
Completed NCT00000282 - Pemoline for Cocaine Abuse - 7 Phase 2
Completed NCT00000306 - Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3 Phase 2
Completed NCT00000278 - Disulfiram for Cocaine-Alcohol Abuse - 3 Phase 2
Completed NCT00000280 - Glutaminergic Agents for Cocaine Abuse - 5 Phase 1
Completed NCT00000314 - M-CPP and Fenfluramine in Cocaine Addicts - 3 Phase 2